Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

How to Make Postmarket Surveillance
More Cost Effective


When it comes to postmarket surveillance (PMS), it’s common for the costs to outweigh the value. But, by working with the right team, you’ll be able to execute a study that maximizes return on investment and minimizes the financial impact of conducting further observational research. Postmarket study challenges that must be addressed include enrollment delays, patient attrition, long-term follow-up, resourcing demands and global payor requirements. This session will provide a case study of one orthopaedic company’s seamless transition between postmarket approval and post-approval studies.

Session Takeaways:

  • Enrollment delays
  • Patient attrition
  • Long-term follow up & staff turnover
  • Resourcing demands
  • Global payer requirements

Who Should Attend

  • Regulatory/Clinical Affairs
  • Research/Development/Design
Vicki Anastasi, Vice President and Global Head, Medical Device and Diagnostics Research, ICON plc

Vicki Anastasi webMs. Anastasi provides leadership to create and foster priority relationships in the medical device and diagnostic marketplace, developing customized programs to meet medical device client needs. She has over twenty-five years of experience in the medical device industry, with over fifteen years specifically focused on global medical device strategic consulting.

Prior to joining the company in 2007, she held senior management roles for medical device companies focused in orthopaedics, cardiovascular, general hospital and general surgical devices. In diagnostics, she held senior positions at companies involved in the development of infectious disease and genetic-based products.

She is actively involved in medical device industry groups, including Advamed, OCTANe, MassMedic and MDMA, where she regularly speaks and participates in medical device focused panels and discussions.